Loading clinical trials...
Loading clinical trials...
AVF Volume Blood Flow Reduction in HD Patients with Chronic Heart Failure
Heart failure with preserved / high cardiac output is a well-known syndrome in patients with high-flow arteriovenous fistula (AVF). However, the threshold for classifying an AVF as high-flow is currently undefined. Cardio-fistular recirculation (CFR) is often used as a criterion, with values greater than 25-30% considered cardiotoxic and associated with adverse outcomes. Additionally, CFR is one of the few easily modifiable risk factors through surgical reduction of AVF volume blood flow (Qa). The study aimed to evaluate the extent of involution of heart structural and functional changes following Qa reduction in patients with heart failure and CFR \> 25%.
Age
18 - 100 years
Sex
ALL
Healthy Volunteers
No
Moscow Regional Research and Clinical Institute
Moscow, Russia
Start Date
December 20, 2018
Primary Completion Date
April 5, 2022
Completion Date
April 5, 2022
Last Updated
February 4, 2025
86
ACTUAL participants
Lead Sponsor
Moscow Regional Research and Clinical Institute (MONIKI)
NCT07191730
NCT07484009
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions